At Oxford BioTherapeutics we are developing revolutionary antibody-drug conjugates for cancer. These have the potential to enhance treatment effectiveness while sparing healthy tissue and reducing side effects. Unlocking the power of these treatments requires precision. Precision targeting, precision delivery and precision cancer eradication. Our mission is simple: to transform patients’ lives with Precision Cancer Therapy.

Oxford BioTherapeutics is developing antibody-drug conjugates targeting a wide variety of cancers that are difficult to treat and consequently have significant unmet medical needs. We have a strong pipeline of in-house development programs, and work closely with a range of partners to ensure we incorporate leading technologies into our revolutionary new treatments.